SeraGene, Inc., of Vancouver, Canada, is addressing limitations in current care standards for
coagulation disorders by delivering innovative therapies that
provide long-lasting control over disordered coagulation. Designed
with life-long use in mind, the SeraGene team has selected high efficacy targets
with a lower potential safety risk to meaningfully improve the quality
of life for those living with coagulation disorders.
The SeraGene technology provides proprietary RNA agents with
liver-targeting drug delivery vehicles to restore hemostasis by
precisely modulating the endogenous expression of clotting
proteins in the blood.